Metlinka

Metformin Hydrochloride, Sitagliptin, the active ingredient in Metlinka, is a Biguanide/DPP‑4 inhibitor combination presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients. It combines metformin’s ability to lower hepatic glucose output with sitagliptin’s enhancement of incretin activity, offering complementary glucose‑lowering effects.

GNH USA supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Metlinka is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

Type 2 diabetes mellitus: improves glycemic control when added to diet, exercise and other antidiabetic agents. Metabolic syndrome: assists in reducing fasting plasma glucose as part of comprehensive risk‑factor management. Combination therapy: used together with insulin or other oral agents to achieve individualized HbA1c targets.

Metlinka may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset (nausea, diarrhea, abdominal discomfort) - Loss of appetite - Headache - Mild hypoglycemia (especially when combined with sulfonylureas)

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia - Acute pancreatitis - Anaphylactic reactions

Before initiating Metlinka, clinicians should consider several safety considerations to minimize risk.

Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. Hepatic function monitoring: use cautiously in patients with liver disease. Cardiovascular disease: monitor for signs of heart failure, especially in elderly. Pregnancy and lactation: avoid unless benefits outweigh potential risks; limited data available. Elderly patients: start at lower dose and titrate slowly. Store at room temperature: keep in original container, protect from moisture and heat.

Metlinka can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate acute renal failure, necessitating temporary discontinuation. - Cimetidine: can raise metformin plasma concentrations, increasing lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: combined use can increase risk of renal dysfunction. - Warfarin: potential alteration of INR, requiring closer monitoring.